Business Description
Onconetix Inc
NAICS : 541713
SIC : 2834
ISIN : US09610B1089
Description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -0.29 | |||||
Debt-to-Equity | -0.72 | |||||
Debt-to-EBITDA | -0.35 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.44 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -144.4 | |||||
3-Year EPS without NRI Growth Rate | -96.1 | |||||
3-Year FCF Growth Rate | -71.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.45 | |||||
9-Day RSI | 44.09 | |||||
14-Day RSI | 46.28 | |||||
6-1 Month Momentum % | -21.34 | |||||
12-1 Month Momentum % | -87.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.29 | |||||
Quick Ratio | 0.28 | |||||
Cash Ratio | 0.21 | |||||
Days Inventory | 598.39 | |||||
Days Sales Outstanding | 97.03 | |||||
Days Payable | 2328.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26.4 | |||||
Shareholder Yield % | 0.76 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 32.59 | |||||
Operating Margin % | -2453.17 | |||||
Net Margin % | -6026.65 | |||||
FCF Margin % | -1907.52 | |||||
ROE % | -1439.26 | |||||
ROA % | -94.12 | |||||
ROIC % | -39.33 | |||||
ROC (Joel Greenblatt) % | -53763.22 | |||||
ROCE % | -130.43 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.14 | |||||
EV-to-EBIT | -0.32 | |||||
EV-to-EBITDA | -0.32 | |||||
EV-to-Revenue | 18.76 | |||||
EV-to-FCF | -0.99 | |||||
Earnings Yield (Greenblatt) % | -312.5 | |||||
FCF Yield % | -448.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ONCO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Onconetix Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.758 | ||
EPS (TTM) ($) | -2.51 | ||
Beta | 0 | ||
Volatility % | 104.06 | ||
14-Day RSI | 46.28 | ||
14-Day ATR ($) | 0.023673 | ||
20-Day SMA ($) | 0.15679 | ||
12-1 Month Momentum % | -87.66 | ||
52-Week Range ($) | 0.1001 - 1.2 | ||
Shares Outstanding (Mil) | 22.33 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Onconetix Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Onconetix Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Onconetix Inc Frequently Asked Questions
What is Onconetix Inc(ONCO)'s stock price today?
The current price of ONCO is $0.14. The 52 week high of ONCO is $1.20 and 52 week low is $0.10.
When is next earnings date of Onconetix Inc(ONCO)?
The next earnings date of Onconetix Inc(ONCO) is 2024-10-18 Est..
Does Onconetix Inc(ONCO) pay dividends? If so, how much?
Onconetix Inc(ONCO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |